HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and raises the price target from $25 to $28.
February 15, 2024 | 5:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Neutral rating on Sage Therapeutics and raises the price target from $25 to $28.
The increase in price target from $25 to $28 by a reputable analyst firm like HC Wainwright & Co. suggests a positive outlook on the stock's value, potentially leading to short-term investor optimism and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100